Managment Team at Galleon Pharmaceuticals

James C. Mannion, Ph.D. - President & CEO and Founder of Galleon

• Jim has a 25 year track record of technical innovation and commercial success in the pharmaceutical industry that includes clinical development (Burroughs Wellcome, Beecham), drug safety (Beecham), regulatory affairs (SmithKline Beecham), business unit development and management (Quintiles), corporate venture capital (Quintiles) and biotechnology senior management (EpiGenesis, Aptus, and Galleon).


• Jim’s scientific and business training includes pharmacy (B.S., Ohio Northern), pharmacy administration (M.S., Purdue), clinical pharmacy (Ph.D., Purdue), clinical drug research/drug development (Post-doctoral fellowship, University of North Carolina) and management (University of Tennessee). Purdue University named Jim as a Distinguished Alumnus in 2002.

Douglas W.P. Hay, Ph.D. - Senior Vice President, Drug Discovery

• Douglas has over 22 years in drug discovery at GlaxoSmithKline (King of Prussia, PA); his last position at GSK was Vice President, Respiratory & Inflammation, Center of Excellence for Drug Discovery, responsible for managing the COPD drug discovery group.


• Douglas obtained his Ph.D. in Physiology/Pharmacology from the University of Strathclyde, Glasgow, Scotland. He is author of over 100 peer-reviewed papers and more than 40 book chapters and reviews, and has co-edited 2 books.

Scott L. Dax, Ph.D. - Senior Director, Head of Medicinal Chemistry

• Scott received his masters and doctorate degrees in chemistry (organic) at The University of Michigan. Scott was also a National Institutes of Health Postdoctoral Fellow at the University of Wisconsin. Scott has twenty years of pharmaceutical research experience in the areas of anti-infectives, CNS agents and analgesia (Hoffmann-LaRoche, Dupont-Merck and Johnson & Johnson).


• Scott has over forty publications, eight issued US patents (ten pending), has written one textbook and served as co-editor for two book series.

Paul Hoskins - Head, Project Management and Planning

• Paul has over 16 years of global pharmaceutical clinical development and GXP compliance experience. Program Management includes Phase 1 to Phase 4 studies that span multiple first in man studies to multicenter global registration programs.


• Paul attended undergraduate at The Ohio State University with a major in biochemistry. He is an ASQ Certified Quality Auditor.